Bivariate and multivariate analysis (stepwise logistic regression) in the 62 children.
| Bivariate Analysis | Multivariate Analysis | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| All Patients, Anti-IFX n = 62 | AB+, Anti-IFX n = 14 | ABâ, n = 48 | OR | Lower | Upper | Significance | OR | Lower | Upper | Significance | |
| Age at IFX treatment start, yrs, mean (SD) | 9.23 (3.40) | 7.01 (3.48) | 9.88 (3.14) | NA | NA | NA | 0.003 | 0.77 | 0.60 | 0.99 | 0.038 |
| Sex, female, n | 44 | 12 | 32 | 3.00 | 0.60 | 15.05 | 0.177 | 1.44 | 0.20 | 10.34 | 0.714 |
| IFX start dose, mg/kg, mean (SD) | 6.03 (1.46) | 5.75 (1.52) | 6.12 (1.45) | NA | NA | NA | 0.424 | 1.00 | 0.60 | 1.67 | 0.997 |
| MTX dose, mg/m2/week, mean (SD)* | 6.19 (1.83) | 6.52 (2.22) | 6.09 (1.72) | NA | NA | NA | 0.607 | 0.90 | 0.65 | 1.25 | 0.535 |
| Systemic corticosteroids, n | 12 | 0 | 12 | 0.00 | 0.00 | â | NA | 0.00 | 0.00 | â | NA |
| Infusion reaction, n | 10 | 7 | 3 | 15.00 | 3.12 | 72.07 | < 0.001 | 11.32 | 1.93 | 66.24 | 0.007 |
| Treatment indication uveitis, n | 26 | 2 | 24 | 0.17 | 0.03 | 0.83 | 0.024 | 0.11 | 0.02 | 0.77 | 0.026 |
Bivariate and multivariate analysis (stepwise logistic regression) of various co-factors with the occurrence of anti-IFX antibodies as dependent variable.
âµ* Mean dose during the study period. AB: antibody; IFX: infliximab; MTX: methotrexate; NA: not applicable.